Granite - Patient-Specific Neoantigen Immunotherapy
From Our Pipeline
Our first oncology product candidate, GRANITE, is a personalized neoantigen-based immunotherapy. It is being evaluated in the Phase 2 portion of a Phase 1/2 clinical study in combination with checkpoint inhibitors for patients with microsatellite stable colorectal cancer (MSS CRC) who have progressed on FOLFOX/FOLFIRI therapy and a second cohort for patients with gastro-esophageal cancer who have progressed on chemotherapy. GRANITE was granted Fast Track designation by the U.S. Food and Drug Administration for the treatment of MSS CRC.
-
Most popular related searches
Details
For each patient, our personalized immunotherapy will start with a routine clinical biopsy. We then utilize our in-house sequencing capabilities with the tumor sample and apply our proprietary EDGE™ platform to derive a set of predicted patient-specific neoantigens likely to be presented on the patient’s tumor. Using these predicted neoantigens, we will then design a personalized immunotherapy containing the relevant neoantigens to be administered by simple intramuscular injection. We intend to deliver the immunotherapy in a community oncology setting where a vast majority of cancer patients are treated.
Routine Biopsy
- Routine FFPE clinical biopsy as input material
Sequencing
- Tumor exome
- Normal exome
- Tumor transcriptome
Neoantigen Prediction
- Gritstone EDGE™
- AI model for tumor antigen prediction trained on human tumor data
Personalized Immunotherapy
- Patient specific predicted neoantigens inserted into Gritstone immunotherapy
Simple Injection
- Immunotherapy administered in conjuction with checkpoint inhibitors
Customer reviews
No reviews were found for Granite - Patient-Specific Neoantigen Immunotherapy. Be the first to review!